赖才达博士毕业于诺华制药与MIT制造研究中心，主要研究动态建模、工艺优化及药物结晶。读博期间，其创办了净水科技新创——AquaFresco，成功研发出一项创新污水循环技术并使其商业化，还赢得了MassChallenge等多项大奖，将大自然的水循环运用到家庭中。另外，赖才达博士曾在头部咨询公司麦肯锡担任策略顾问，协助500强药企制定数字化策略。

作为人工智能驱动药物研发的先锋，赖才达博士将药物制剂、递送技术和机器学习相结合，为剂泰医药技术平台奠定了基础。同时，运用多年创业经验和数字化策略，带领剂泰医药快速发展。

He obtained his Ph.D. at the Novartis-MIT Center, and his research is primarily on dynamic modeling, process optimization, and drug crystallization. During his tenure at MIT, Dr. Lai founded AquaFresco, a water-tech startup, and successfully developed and commercialized an innovative wastewater recycle technology that reinvented laundry by borrowing ideas from nature. This innovation won him the prestigious MassChallenge prize, among other major awards. Dr. Lai had also served as a strategic consultant at McKinsey & Company, a top consulting firm, helping some Fortune 500 pharmaceutical companies shape their digital strategy.

As a pioneer in AI-driven drug development, Dr. Lai has laid the foundation for METiS’s technology platforms by integrating drug formulation, delivery technology and machine learning. Meanwhile, he leads METiS to its fast development by leveraging his entrepreneurial experience and expertise in digital strategy.